Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

ClinicalTrials.gov ID: NCT03139370

Public ClinicalTrials.gov record NCT03139370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.

Study identification

NCT ID: NCT03139370
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Kite, A Gilead Company; Industry
Enrollment: 16 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Drug · Device

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 27, 2017 (Actual)
Primary completion: Jun 30, 2021 (Actual)
Completion: Jun 4, 2023 (Actual)
Last update posted: Aug 25, 2023

2017 – 2023

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	—
USC/Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
UCLA Hematology/Oncology	Los Angeles	California	90095	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
H. Lee Moffitt Cancer and Research Institute	Tampa	Florida	33612	—
University of Chicago	Chicago	Illinois	60640	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Baylor Scott & White Charles A. Sammons Cancer Center	Dallas	Texas	75246	—
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03139370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 25, 2023 · Synced Nov 8, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03139370 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →